For example, as depicted in Figure 3, Factor H targeting by factor D inhibitor, Lampalizumab (Roche AG, Basel, Switzerland) is in clinical trials for age-related macular degeneration (AMD) and orphan renal disease. The gene discussed is LIF; the disease is age-related macular degeneration.